Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: a nationwide cross-sectional survey.
- Publisher:
- Oxford University Press (OUP)
- Publication Type:
- Journal Article
- Citation:
- Japanese journal of clinical oncology, 2019, 49, (5), pp. 486-490
- Issue Date:
- 2019-05
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
PAC-10036478.pdf | Published version | 155.95 kB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Matsuoka, H | |
dc.contributor.author | Tagami, K | |
dc.contributor.author | Ariyoshi, K | |
dc.contributor.author | Oyamada, S | |
dc.contributor.author | Kizawa, Y | |
dc.contributor.author | Inoue, A | |
dc.contributor.author | Koyama, A | |
dc.date.accessioned | 2020-06-05T01:15:59Z | |
dc.date.available | 2019-01-04 | |
dc.date.available | 2020-06-05T01:15:59Z | |
dc.date.issued | 2019-05 | |
dc.identifier.citation | Japanese journal of clinical oncology, 2019, 49, (5), pp. 486-490 | |
dc.identifier.issn | 0368-2811 | |
dc.identifier.issn | 1465-3621 | |
dc.identifier.uri | http://hdl.handle.net/10453/141122 | |
dc.description.abstract | Cancer-related neuropathic pain (CNP) requires therapy involving multiple pharmaceuticals, including anticonvulsants and antidepressants; however, strong evidence to support this practice is limited. This study is a cross-sectional questionnaire-based survey. As the standard dose of adjuvant analgesics for CNP refractory to opioid therapy is not clear, the purpose of this study is to clarify the opinions of specialists about the usage of duloxetine and pregabalin for patients with CNP refractory to opioid therapy. Two hundred and eight certified palliative care specialists were surveyed and a total of 87 (42%) responses were analyzed. Twenty-five percent of specialists had considered increasing duloxetine doses up to 60 mg/day and 58% had considered increasing pregabalin doses up to 300 mg/day for CNP refractory to opioid therapy. However, 23% of the specialists succeeded in increasing duloxetine doses up to 60 mg/day and 17% in increasing pregabalin doses up to 300 mg/day, respectively. | |
dc.format | ||
dc.language | eng | |
dc.publisher | Oxford University Press (OUP) | |
dc.relation.ispartof | Japanese journal of clinical oncology | |
dc.relation.isbasedon | 10.1093/jjco/hyz002 | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | 1112 Oncology and Carcinogenesis | |
dc.subject.classification | Oncology & Carcinogenesis | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Neuralgia | |
dc.subject.mesh | Analgesics | |
dc.subject.mesh | Analgesics, Opioid | |
dc.subject.mesh | Adjuvants, Pharmaceutic | |
dc.subject.mesh | Palliative Care | |
dc.subject.mesh | Cross-Sectional Studies | |
dc.subject.mesh | Attitude of Health Personnel | |
dc.subject.mesh | Dose-Response Relationship, Drug | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Physicians | |
dc.subject.mesh | Japan | |
dc.subject.mesh | Female | |
dc.subject.mesh | Male | |
dc.subject.mesh | Specialization | |
dc.subject.mesh | Surveys and Questionnaires | |
dc.subject.mesh | Pregabalin | |
dc.subject.mesh | Duloxetine Hydrochloride | |
dc.subject.mesh | Cancer Pain | |
dc.subject.mesh | Adjuvants, Pharmaceutic | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Analgesics | |
dc.subject.mesh | Analgesics, Opioid | |
dc.subject.mesh | Attitude of Health Personnel | |
dc.subject.mesh | Cancer Pain | |
dc.subject.mesh | Cross-Sectional Studies | |
dc.subject.mesh | Dose-Response Relationship, Drug | |
dc.subject.mesh | Duloxetine Hydrochloride | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Japan | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neuralgia | |
dc.subject.mesh | Palliative Care | |
dc.subject.mesh | Physicians | |
dc.subject.mesh | Pregabalin | |
dc.subject.mesh | Specialization | |
dc.subject.mesh | Surveys and Questionnaires | |
dc.title | Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: a nationwide cross-sectional survey. | |
dc.type | Journal Article | |
utslib.citation.volume | 49 | |
utslib.location.activity | England | |
utslib.for | 1112 Oncology and Carcinogenesis | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2020-06-05T01:15:54Z | |
pubs.issue | 5 | |
pubs.publication-status | Published | |
pubs.volume | 49 | |
utslib.start-page | 486 | |
utslib.citation.issue | 5 |
Abstract:
Cancer-related neuropathic pain (CNP) requires therapy involving multiple pharmaceuticals, including anticonvulsants and antidepressants; however, strong evidence to support this practice is limited. This study is a cross-sectional questionnaire-based survey. As the standard dose of adjuvant analgesics for CNP refractory to opioid therapy is not clear, the purpose of this study is to clarify the opinions of specialists about the usage of duloxetine and pregabalin for patients with CNP refractory to opioid therapy. Two hundred and eight certified palliative care specialists were surveyed and a total of 87 (42%) responses were analyzed. Twenty-five percent of specialists had considered increasing duloxetine doses up to 60 mg/day and 58% had considered increasing pregabalin doses up to 300 mg/day for CNP refractory to opioid therapy. However, 23% of the specialists succeeded in increasing duloxetine doses up to 60 mg/day and 17% in increasing pregabalin doses up to 300 mg/day, respectively.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph